Zydus Cadila gets USFDA approval to market Mesalamine Delayed - Release Tablets USP, 1.2 g

In US market

Zydus Cadila announced that USFDA has given its final approval to market Mesalamine Delayed - Release Tablets USP, 1.2 g in the US market. Zydus Cadila was the first to file an Abbreviated New Drug Application for a generic version of Lialda (mesalamine). The product will be manufactured at the Maurya manufacturing facility.

Powered by Capital Market - Live News